E-resources
PDF-
Shiboski, Caroline H.; Baer, Alan N.; Shiboski, Stephen C.; Lam, Mi; Challacombe, Stephen; Lanfranchi, Hector E.; Shirlaw, Penelope; Srinivasan, Muthiah; Umehara, Hisanori; Vivino, Frederick B.; Akpek, Esen; Bunya, Vatinee; Vollenweider, Cristina F.; Greenspan, John S.; Daniels, Troy E.; Criswell, Lindsey A.; Cox, D.; Jordan, R.; Lee, D.; Sack, K.; Whitcher, J.; Lietman, T.; McNamara, N.; Wu, A.; DeSouza, Y.; Drury, D.; Do, A.; Scott, L.; Nespeco, J.; Whiteford, J.; Margaret, M.; Adler, I.; Smith, A. C.; Bisio, A. M.; Gandolfo, M. S.; Heidenreich, A. M.; Chirife, A. M.; Keszler, A.; Daverio, S.; Kambo, V.; Jiang, Y.; Xu, D.; Su, J.; Zhao, Y.; Dong, Y.; Du, D.; Wang, H.; Li, Z.; Xiao, J.; Wu, Q.; Zhang, C.; Meng, W.; Zhang, J.; Johansen, S.; Hamann, S.; Lindegaard, J.; Schiødt, Julie; Holm, Helena; Helin, P.; Ibsen, P.; Manniche, A. M.; Kreutzmann, S. P.; Masaki, Y.; Sakai, T.; Sugai, S.; Kitagawa, K.; Shibata, N.; Honjo, M.; Kurose, N.; Nojima, T.; Kawanami, T.; Sawaki, T.; Fujimoto, K.; Kirkham, B.; Larkin, G.; Odell, E.; Morgan, P.; Fernandes‐Naglik, L.; Varghese‐Jacob, B.; Seghal, S.; Mishra, R.; Massaro‐Giordano, M.; Abboud, S. K.; Pinto, A.; Sia, Y. W.; Dow, K.; Ingrodi, S.; Henderson, W.; Gourin, C.; Keyes, A.; Mascarenhas, J.; Das, M.; Kumar, A.; Joshi, Pallavi; Banushree, R.; Kim, U.; Babu, B.; Ram, A.; Kannappan, Saravanan; Kalyani, N.
Arthritis care & research (2010), February 2018, Volume: 70, Issue: 2Journal Article
Objective To explore changes in the phenotypic features of Sjögren's syndrome (SS), and in SS status among participants in the Sjögren's International Collaborative Clinical Alliance (SICCA) registry over a 2–3‐year interval. Methods All participants in the SICCA registry who were found to have any objective measures of salivary hypofunction, dry eye, focal lymphocytic sialadenitis in minor salivary gland biopsy, or anti‐SSA/SSB antibodies were recalled over a window of 2 to 3 years after their baseline examinations to repeat all clinical examinations and specimen collections to determine whether there was any change in phenotypic features and in SS status. Results As of September 15, 2013, a total of 3,514 participants had enrolled in SICCA, and among 3,310 eligible, 771 presented for a followup visit. Among participants found to have SS using the 2012 American College of Rheumatology (ACR) classification criteria, 93% again met the criteria after 2 to 3 years, and this proportion was 89% when using the 2016 ACR/European League Against Rheumatism (EULAR) criteria. Among those who did not meet ACR or ACR/EULAR criteria at baseline, 9% and 8%, respectively, had progressed and met them at followup. Those with hypergammaglobulinemia and hypocomplementemia at study entry were, respectively, 4 and 6 times more likely to progress to SS by ACR criteria than those without these characteristics (95% confidence interval 1.5–10.1 and 1.8–20.4, respectively). Conclusion While there was stability over a 2–3‐year period of both individual phenotypic features of SS and of SS status, hypergammaglobulinemia and hypocomplementemia at study entry were predictive of progression to SS.
